- A blocked-randomization design was intended to give roughly four times
as many patients in the Atomoxetine group which makes direct comparisons
between the groups more difficult.1
- Only 50-60% of both groups completed the 10-week study period, but
>90% of both groups had at least one postbaseline visit which was
carried forward to permit inclusion in the final analysis.1
- Atomoxetine caused statistically significant increases in heart rate
and blood pressure which were not clinically significant. This has been
confirmed in other studies.1-4
- Atomoxetine was associated with slightly greater weight loss than
Methylphenidate (0.6 kg vs 0.1 kg over 10 weeks). Other studies have
suggested catch-up growth thereafter.1-4
- This particular study found statistically significant increases in
vomiting and somnolence in the Atomoxetine group, and no statistically
significant difference in the occurrence of insomnia. Most other studies
have shown Atomoxetine to cause less insomnia than Methylphenidate,
and not to be associated with other side effects other than weight loss
- Atomoxetine works via norepinephrine reuptake inhibition.
- Costs for one month supply (as per UM Outpatient Pharmacy):
CJ, Heligenstein JH, Dittman R, et al: Atomoxetine and methylphenidate
treatment in children with ADHD: A prospective, randomized, open-label
trial. J Am Acad Child Adolesc Psychiatry 2002;41:776-84.
D, Faries D, Wernicke J, et al: Atomoxetine in the treatment of children
and adolescents with attention-deficit/hyperactivity disorder; A randomized,
placebo-controlled, dose-response study. Pediatrics 2001;108:e83.
D, Allen AJ, Busner J, et al: Once-daily atomoxetine treatment for children
and adolescents with attention deficit hyperactivity disorder: A randomized,
placebo-controlled study. Am J Psychiatry 2002;159:1896-901.
J, Heiligenstein JH, Faries DE: Efficacy of atomoxetine versus placebo
in school-age girls with attention-deficit/hyperactivity disorder. Pediatrics